Johnson & Johnson Reports Record $94.2 Billion in 2025 Revenue, On Track to Surpass $100 Billion in 2026

　　【Pharmaceutical Network Enterprise NewsRecently, Johnson & Johnson announced its full-year 2025 earnings report, delivering impressive results with total annual sales reaching $94.2 billion, driven by strong performance in core businesses. Meanwhile, Johnson & Johnson issued its 2026 earnings guidance, forecasting sales to exceed $100 billion, indicating that the company is entering a new phase of accelerated growth.
 

According to Johnson & Johnson's 2025 financial report, the company's total sales for the full year of 2025 reached $92.4 billion, a year-on-year increase of 6.0%; net profit reached $26.8 billion, with diluted earnings per share (EPS) at $11.03, a year-on-year increase of 90.5%; adjusted EPS was $10.79, an increase of 8.1%.
 

Among them, Johnson & Johnson Medical Technologies reported an income of 33.792 billion US dollars in 2025, with a growth of 6.1%. In terms of segments, cardiovascular, surgery, and ophthalmology are currently the key areas of focus for the company.
 

The report shows that in 2025, the sales revenue of Johnson & Johnson's cardiovascular department increased by 15.8% year-on-year to 8.928 billion US dollars. Among them, the sales revenue of electrophysiology increased by 7% year-on-year to 5.634 billion US dollars, mainly due to the growth of surgeries within the integrated product portfolio, commercial execution, and the launch of new products such as VARIPULSE. ABIOMED’s sales revenue increased by 17.1% year-on-year to 1.751 billion US dollars; SHOCKWAVE’s sales revenue increased by 22.9% year-on-year to 1.146 billion US dollars.
 

In addition, surgical sales increased by 3% year-on-year to USD 10.137 billion, driven by the accelerated launch of new products in the biosurgery field, the widespread application of wound closure technology, and excellent commercial execution. Ophthalmology sales grew by 6.3% year-on-year to USD 5.486 billion, benefiting from product innovation, strong demand for premium intraocular lenses, and outstanding commercial execution. Orthopedic sales increased by 1.1% year-on-year to USD 9.258 billion. Currently, orthopedic growth momentum has been curbed due to the transformation of the orthopedics business and the impact of China's centralized procurement policies.
 

In the innovative pharmaceuticals sector, the company generated $60.4 billion in revenue in 2025, covering six major disease areas: oncology, immunology, neuroscience, cardiovascular and cerebrovascular, surgery, and eye health.
 

In the field of oncology, DARZALEX (daratumumab) is projected to reach $14.4 billion in sales by 2025, remaining a core pillar of the company. The strong growth of this drug is attributed, on one hand, to the approval of its subcutaneous formulation, daratumumab Faspro, in 2019. On the other hand, exploration of combination regimens may further drive the drug's sales growth. Additionally, Carvykti (cilta-cel) has seen increased adoption in second-line treatment, with revenue reaching $1.887 billion in 2025, representing a 95.9% increase from the same period last year ($963 million).
 

Other growth drivers include the immunology product Tremfya (guselkumab), with sales expected to grow 40% to approximately $5.2 billion by 2025; and the neuroscience product Spravato, with sales projected to increase 57% to reach $1.7 billion by 2025.
 

Johnson & Johnson stated that 2025 is a pivotal year for the company to achieve leapfrog development, ushering in a new era of accelerated growth. By region, in 2025, sales of Johnson & Johnson’s medical technology in the United States increased by 6.6% year-on-year, reaching $17.408 billion; international market sales grew by 5.5% year-on-year, amounting to $16.384 billion. Looking ahead to 2026, the company has issued earnings guidance, projecting sales growth between 6.2% and 7.2%. Based on this forecast, the company's sales in 2026 are expected to reach $100 billion. Industry insiders noted that with the penetration of new medical technology products and the continued scaling up of innovative drugs, Johnson & Johnson is well-positioned to maintain rapid growth in the global healthcare market through technological innovation and strategic optimization, fulfilling its promise of achieving $100 billion in growth.
 

Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.